Morning Alert..
*No reciprocal tariff reprieve for India, signals Trump in address to Cong*
United States (US) President Donald Trump, in his address to Congress on Tuesday, signaled that there would be no reprieve for India from the reciprocal tariffs set to take effect on April 2. Through reciprocal tariffs, the US aims to match other countries’ tariffs, taxes, and non-tariff barriers. “On average, the European Union, China, Brazil, India, Mexico and Canada, and countless other nations charge us tremendously higher tariffs than we charge them. It’s very unfair. India charges us auto tariffs higher than 100 per cent…On April 2, reciprocal tariffs kick in and whatever they tariff us other countries, we will tariff them. Whatever they tax us, we will tax them,” Trump said addressing a joint session of the Congress. This is not the first time Trump has called India a high-tariff nation. In the past, he has made it clear that Washington would not exempt India from reciprocal tariffs. This development makes things complex for India-US relations, especially since last month. In February, Prime Minister Narendra Modi and Trump had announced their intention to sign a mutually beneficial trade agreement (BTA) within the next seven to eight months.
*Global market action*
Dow Jones – Down by 0.08% or 32.88 points
FTSE – Down by 0.04% or 3.16 points
CAC – Up by 1.54% or 125.83 points
DAX – Up by 3.27% or 754.22 points
Gift Nifty – Up by 0.30% or 66.50 points
*FII/DII activities*
FII – Sold 2895.04Cr worth of shares
DII – Bought 3370.60Cr worth of shares.
*Major Indian Indices PE*
Nifty 50 – 19.9x
Nifty Bank – 12.7x
*Stocks with high delivery percentage*
JK Cement Ltd – 87.2%
Max Financial Services Ltd – 86.3%
Timken India Ltd – 85.7%
Dr. Lal Pathlabs Ltd – 85.3%
Tata Consumer Products Ltd – 82.2%
*Commodities updates*
Gold – Rs 85849/10gm, Silver – Rs 97537/kg, Brcrude – Rs 5752/barrel, Copper – Rs 880.3/kg.
*Corporate News*
Wipro Limited launched TelcoAl360 to transform operations for telcos by leveraging Al
Zydus Lifesciences Limited received final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.